J Neuroophthalmol. 2024 Jun 1;44(2):e244-e245. doi: 10.1097/WNO.0000000000001793. Epub 2023 Jan 4.
NO ABSTRACT
PMID:38741250 | DOI:10.1097/WNO.0000000000001793
Recent Content
- Genetic mutations do not hinder FLAG chemotherapy in rare blood cancer
- Cadonilimab combo boosts survival in advanced pancreatic cancer patients
- Risk for second primary malignancies in patients with multiple myeloma: a systematic review and meta-analysis
- New targeted therapy Ojemda approved in EU for pediatric glioma
- Mapping the Landscape of Quality of Life in Smoldering Multiple Myeloma Clinical Trials: A Systematic Review
- Mo-Rez shows strong early responses in ovarian, endometrial cancers
- FDA grants fast track status to oral therapy for hard-to-treat myeloma
- Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial
- Concordance and prognostic value of bone-marrow MRD and PET-CT in multiple myeloma: a systematic review and meta-analysis
- Advocacy group marks AML Awareness Day with interactive webpage launch